Björn Frendéus

This paper evaluates two TNFR2-targeting antibodies, showing ligand-blocking antibodies deplete T regs and reprogram myeloid cells, while agonists directly co-stimulate T and NK cells, both leading to anti-tumor effects.

This study shows that FcγRIIb promotes α-syn propagation and neurotoxicity in vivo, suggesting it as a therapeutic target for synucleinopathies.